Measurable Residual Disease (MRD) Focus

Understanding Clinical Endpoints In Measurable Residual Disease
Latest Videos Videos by Disease Videos by Congress Podcasts Features E-Learning Expert Editorial Board

Welcome to Measurable Residual Disease (MRD) Focus.

Explore the cutting-edge updates in MRD by disease type, including expert interviews from major international congresses, podcasts and e-learning.

MRD is the term used to describe a small number of cancer cells remaining in patients following treatment, which are below the level of routine morphological detection1,2. Even when a patient is in remission it is possible for them to be ‘MRD positive’. The level of MRD can, theoretically, be used as a prognostic indicator to determine treatment efficacy and to detect cancer recurrence. MRD status is now increasingly measured as an endpoint in clinical trials for haematological malignancies, with the goal of treatment being MRD negativity.

  1. Ossenkoppele G, Schuurhuis GJ. MRD in AML: time for redefinition of CR? Blood. 2013 Mar 21; 121(12): 2166-2168.
  2. Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018 Jun 12; 2(11): 1356-1366.

Videos by Disease

Multiple Myeloma
CLL
Lymphoma
AML
ALL
MDS
2:38
Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more
Maria-Victoria Mateos • 12 May 2023
4:02
The diagnostic and prognostic value of mass spectrometry in multiple myeloma
Noemí Puig • 13 May 2023
3:12
Should we delay transplantation in patients with standard-risk multiple myeloma?
Paul Richardson • 12 May 2023
1:25
Using MRD to improve prognostication during the maintenance phase of myeloma treatment
Bruno Paiva • 12 May 2023
View All Videos
1:10
GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL
Talha Munir • 24 Apr 2023
0:48
The current role of MRD in CLL and future outlooks
Talha Munir • 12 Dec 2022
1:23
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
Talha Munir • 12 Dec 2022
1:17
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL
Talha Munir • 12 Dec 2022
View All Videos
8:37
Safety and efficacy of CD7-targeted CAR-T therapy in patients with R/R T-ALL and T-LBL
Peihua Lu • 12 Dec 2022
7:35
Survey on the evaluation and management of DLBCL following suboptimal response to CAR-T therapy
Nausheen Ahmed • 20 Feb 2023
5:12
Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL
Jia Ruan • 10 Dec 2022
2:32
The use of PET and ctDNA for risk stratification & to guide treatment decisions in Hodgkin lymphoma
Peter Borchmann • 12 Dec 2022
View All Videos
3:12
Should we delay transplantation in patients with standard-risk multiple myeloma?
Paul Richardson • 12 May 2023
1:23
Indications for autologous stem cell transplantation in AML
Norbert-Claude Gorin • 23 Apr 2023
0:54
Clinical responses of pediatric patients with R/R acute leukemia treated with aza/ven
Sarah Tasian • 16 Apr 2023
1:31
The safety and efficacy of revumenib in patients with KMT2A-rearranged or NPM1-mutated AML
Eytan Stein • 12 Dec 2022
View All Videos
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023
View All Videos
3:12
Should we delay transplantation in patients with standard-risk multiple myeloma?
Paul Richardson • 12 May 2023
5:00
Phase I study of ven/aza maintenance therapy following ven/FluBu2 RIC alloSCT in high-risk MDS/AML
Jacqueline Garcia • 12 Dec 2022
2:08
Venetoclax-based quadruplet therapy with trametinib for patients with RAS-mutated AML and MDS
Andrius Žučenka • 11 Dec 2022
3:58
Orca-T with tacrolimus or TAC/MMF/PTCy as GvHD prophylaxis in allotransplant recipients
Caspian Oliai • 12 Dec 2022
View All Videos

Videos by Congress

COMy 2023
ISAL 2023
ASH 2022
SOHO Italy 2022
ERIC 2022
SOHO 2022
IMS 2022
ISA 2022
EHA 2022
ASCO 2022
COMy 2022
TCT 2022
2:38
Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more
Maria-Victoria Mateos • 12 May 2023
4:02
The diagnostic and prognostic value of mass spectrometry in multiple myeloma
Noemí Puig • 13 May 2023
3:12
Should we delay transplantation in patients with standard-risk multiple myeloma?
Paul Richardson • 12 May 2023
1:25
Using MRD to improve prognostication during the maintenance phase of myeloma treatment
Bruno Paiva • 12 May 2023
View All Videos
1:26
The current role of MRD in AML and challenges with implementing this in clinical practice
Thomas Cluzeau • 20 Mar 2023
3:25
Personalizing therapy in AML: current status and future outlooks
Marina Konopleva • 20 Mar 2023
1:20
The prognostic value of CD34+CD38- leukemic stem cell frequency in AML
Jacqueline Cloos • 20 Mar 2023
1:41
Implementing MRD in clinical practice for patients with intermediate-risk AML
Jacqueline Cloos • 20 Mar 2023
View All Videos
1:31
The safety and efficacy of revumenib in patients with KMT2A-rearranged or NPM1-mutated AML
Eytan Stein • 12 Dec 2022
0:48
The current role of MRD in CLL and future outlooks
Talha Munir • 12 Dec 2022
1:23
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
Talha Munir • 12 Dec 2022
1:17
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL
Talha Munir • 12 Dec 2022
View All Videos
2:01
The role of MRD in CLL patients with high-risk cytogenetics & future perspectives
Massimo Massaia • 25 Oct 2022
1:39
The growing role of MRD as a clinical endpoint in CLL
Massimo Massaia • 25 Oct 2022
1:15
The potential role of MRD in treating CLL patients receiving continuous therapy
Massimo Massaia • 25 Oct 2022
1:50
The possibility of using MRD status to drive treatment in AML
Alessandro Isidori • 24 Oct 2022
View All Videos
2:07
Moving towards time-limited treatment in frontline CLL
Florence Cymbalista • 7 Oct 2022
1:59
The role of MRD as a prognostic & predictive biomarker in CLL
Othman Al-Sawaf • 6 Oct 2022
3:51
The role of frontline chemoimmunotherapy in the era of novel agents in CLL
Michel van Gelder • 7 Oct 2022
2:35
The role of MRD in clinical decision-making in R/R CLL
Lydia Scarfò • 6 Oct 2022
View All Videos
1:09
Using MRD and mutational analysis when selecting patients with T-ALL for transplantation
Josep-Maria Ribera • 3 Oct 2022
5:16
Approaches to and the use of MRD in ALL
Selina Luger • 6 Oct 2022
1:33
Updates from the IKEMA trial: Isa-Kd versus Kd in R/R multiple myeloma
Thomas Martin • 30 Sep 2022
5:05
Determining the most suitable consolidation therapies for AML by defining patient risk group
Selina Luger • 6 Oct 2022
View All Videos
4:16
The prognostic value of MRD in multiple myeloma & MRD-guided therapy
Francesco Maura • 22 Aug 2022
1:53
Factors to consider for the optimal management of relapse in multiple myeloma
Yael Cohen • 27 Jul 2022
2:33
Predicting response to CAR-T therapy with multi-omic approaches
Yi Lin • 25 Aug 2022
1:28
MagnetisMM-7: elranatamab vs lenalidomide following autoHSCT in MRD-positive newly diagnosed myeloma
Maria-Victoria Mateos • 25 Aug 2022
View All Videos
2:13
Advances & unanswered questions about the role of MRD in AL amyloidosis
Andrew Staron • 5 Sep 2022
3:19
Impact of BM MRD status on the quality of organ response in AL amyloidosis
Rajshekhar Chakraborty • 7 Sep 2022
1:11
AL amyloidosis poster highlights from ISA
Paolo Milani • 7 Sep 2022
1:53
The prognostic role of MRD in AL amyloidosis
Andrew Staron • 5 Sep 2022
View All Videos
1:03
The importance of circulating tumor DNA in patients with primary CNS lymphoma
Won-Seog Kim • 11 Jun 2022
2:34
Exploring chemotherapy-free induction treatment for patients with Ph+ ALL
Robin Foà • 11 Jun 2022
5:39
Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL
Peihua Lu • 16 Jun 2022
1:30
Triplet combinations in FLT3-mutated AML
Shai Shimony • 13 Jun 2022
View All Videos
1:39
How can MRD guide treatment of AML?
Christopher Hourigan • 4 Jun 2022
1:11
Current role of MRD in AML
Christopher Hourigan • 4 Jun 2022
1:09
Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT
Christopher Hourigan • 4 Jun 2022
1:05
Key takeaways in leukemia at ASCO 2022
Eunice Wang • 3 Jun 2022
View All Videos
0:57
Highlights and debates at COMy 2022
Sagar Lonial • 14 May 2022
1:51
Is cure possible in multiple myeloma?
Mohamad Mohty • 13 May 2022
1:24
CD38-targeting triplets for myeloma
Michele Cavo • 17 May 2022
2:46
The impact of daratumumab on the myeloma treatment landscape
Claudio Cerchione • 13 May 2022
View All Videos
2:04
Autologous transplantation followed by maintenance vs maintenance alone in patients with MCL
Peter Riedell • 27 Apr 2022
1:05
Are we ready for MRD-guided therapy in multiple myeloma?
Radhika Bansal • 11 Apr 2022
3:20
Second cord blood transplant for patients who relapse following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
2:25
CARTITUDE-5: VRd + cilta-cel or Rd in newly diagnosed multiple myeloma
Saad Usmani • 8 Apr 2022
View All Videos

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals